Testosterone for women: what the evidence supports, and where clinicians disagree

Testosterone is the most requested and least regulated hormone in menopause care right now. Clinics prescribe it for fatigue, brain fog, low motivation, muscle loss, and libido. Specialist societies endorse exactly one of those uses. That gap is why the debate resurfaced in headlines this week, and why women are getting radically different answers depending on which clinic they walk into.

Here is what the evidence actually supports, where the disagreement is genuine, and what to ask before you start.

What testosterone does in the female body

Women produce testosterone in the ovaries and adrenal glands, in quantities roughly 10 to 20 times lower than men. Levels decline gradually with age — the fall begins in the 30s and is not tied to the menopause transition the way estrogen is. Removal of the ovaries, by contrast, cuts circulating testosterone roughly in half, abruptly.

Testosterone is not a spare part. It is a substrate for estradiol production and acts directly on androgen receptors in brain, bone, muscle, and genital tissue. The biology makes a broad benefit plausible. The trial evidence is much narrower than the biology.

The one evidence-based indication

The 2019 Global Consensus Position Statement on testosterone therapy for women — endorsed by The Menopause Society, the International Menopause Society, the Endocrine Society, and others — reached a specific conclusion after reviewing the randomized trials: the only indication with sufficient evidence is hypoactive sexual desire disorder (HSDD) in postmenopausal women.

For that indication, transdermal testosterone at physiological female doses improves sexual desire, arousal, orgasm frequency, and sexual self-image versus placebo. The effect is real but modest — roughly one additional satisfying sexual event per month in pooled data. Meaningful for many women; not transformative for all.

Where the evidence runs out

For every other commonly marketed use, the consensus statement found the data insufficient:

• Fatigue and energy — not supported by randomized data.
• Cognition and brain fog — not supported.
• Mood and depression — not supported as a primary treatment.
• Bone density — insufficient evidence to recommend it for this purpose.
• Lean muscle mass and body composition — insufficient at physiological doses.
• Use in perimenopausal (still-cycling) women — not evaluated in adequate trials. This is the specific point dividing clinicians in current coverage.

"Insufficient evidence" is not the same as "does not work." It means the trials that would answer the question have not been run at adequate size and duration. Prescribing into that gap is a judgment call, not a violation — but it should be named as one.

The supply problem nobody mentions

In the United States there is no testosterone product approved by the FDA for women. Every prescription is either an off-label fraction of a male product or a compounded preparation.

That creates two practical hazards:

• Dosing precision. A male gel pump delivers a dose in the range a woman needs across a full week. Splitting it accurately is difficult, and inconsistent dosing is the most common reason women end up with supraphysiological levels.
• Compounded pellets. Subcutaneous pellets routinely produce levels well above the female physiological range and cannot be removed once inserted. The Global Consensus Statement explicitly recommends against doses that produce supraphysiological concentrations, and specifically cautions against compounded formulations of uncertain content. Pellets are the single most common route to androgenic side effects we see described by patients.

Side effects, in order of likelihood

At correctly dosed physiological levels, testosterone is generally well tolerated. Above that range:

• Acne and oily skin
• Increased facial or body hair
• Scalp hair thinning
• Voice deepening — potentially irreversible
• Clitoral enlargement — potentially irreversible
• Mood irritability
• Adverse lipid changes, particularly with oral formulations (which are not recommended)

The irreversible effects are the reason dosing discipline matters more here than with estradiol. Long-term cardiovascular and breast-safety data for testosterone in women remain limited, which is a separate argument for staying inside the physiological range.

What this means for you

If you are considering testosterone:

1. Fix estrogen first. Low desire in menopause is frequently driven by vaginal dryness, pain with sex, and untreated sleep disruption. Local vaginal estrogen and systemic estradiol resolve a substantial share of what gets attributed to low testosterone. Testosterone added onto an untreated estrogen deficiency tends to disappoint.
2. Expect a baseline total testosterone level — not to diagnose deficiency (no threshold defines it in women), but to establish a starting point and rule out an already-elevated level.
3. Insist on transdermal dosing at physiological female doses, and expect a recheck of levels within 3 to 6 weeks and periodically thereafter.
4. Set a trial endpoint. The consensus guidance suggests reassessing at 3 to 6 months and stopping if there is no meaningful benefit.
5. Decline pellets unless you have exhausted transdermal options and fully understand that the dose cannot be withdrawn.
6. Ask your clinician directly whether they are prescribing for HSDD or for an off-label indication. A clinician who will not distinguish between the two is not a clinician who will manage your levels carefully.

The honest summary

Testosterone is a legitimate and under-prescribed tool for one problem, and an aggressively over-marketed one for several others. The divide among clinicians is not fundamentally about whether testosterone works — it is about whether prescribing ahead of the evidence, in a market with no approved female product, serves women well. Our position is that it can, when the indication is named honestly, the dose stays physiological, and the levels are actually monitored.

Sources

• Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019). https://www.menopause.org/
• The Menopause Society (NAMS), 2022 Hormone Therapy Position Statement. https://www.menopause.org/
• Endocrine Society clinical guidance on androgen therapy in women. https://www.endocrine.org/
• ACOG, Female Sexual Dysfunction (Practice Bulletin). https://www.acog.org/
• FDA, compounded hormone preparations and testosterone labeling. https://www.fda.gov/

This article is health education, not medical advice. Testosterone therapy requires individualized evaluation and monitoring by a licensed clinician.

Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026